Daily Cosmetic Research Analysis
Analyzed 32 papers and selected 3 impactful papers.
Summary
A scalable human liver-on-a-chip platform showed strong predictive performance for drug-induced liver injury, including testing of cosmetic ingredients, advancing non-animal safety assessment. A randomized, double-blind trial in Chinese sensitive skin demonstrated that a supramolecular bakuchiol plus Terminalia chebula serum improved barrier function and photoaging parameters over 28 days. A novel 1550 nm non-ablative resurfacing laser with Focal Point Technology improved acne scars across all Fitzpatrick skin types with blinded, significant ECCA score gains and favorable tolerability.
Research Themes
- Non-animal safety assessment for cosmetics and drugs
- Sensitive-skin anti-aging interventions
- Energy-based devices for scar remodeling across diverse skin types
Selected Articles
1. A Scalable Human Liver-on-a-Chip Platform for Predictive Safety Assessment.
Using the OC-Plex microfluidic platform, primary human hepatocytes retained long-term function and enabled multi-parametric detection of acetaminophen hepatotoxicity. Across 17 reference drugs and cosmetic ingredients, the model achieved 85.7% sensitivity, 100% specificity, and 92.3% accuracy, indicating strong potential for scalable, human-relevant safety testing.
Impact: This work addresses cost, scalability, and validation barriers limiting adoption of organ-on-chip methods, delivering quantitative performance against human toxicity benchmarks.
Clinical Implications: While preclinical, the platform could accelerate cosmetic and pharmaceutical safety screening, reduce animal testing, and flag hepatotoxic liabilities earlier in development.
Key Findings
- Primary human hepatocytes maintained albumin/urea production and CYP expression over extended culture.
- Detected acetaminophen-induced hepatotoxicity across 6 readouts (albumin, viability, CK18, urea, CYP3A4 activity, mitochondrial function).
- Across 17 compounds (including cosmetic ingredients), achieved 85.7% sensitivity, 100% specificity, and 92.3% accuracy.
Methodological Strengths
- Multi-parametric mechanistic readouts in a human-relevant microphysiological system
- Use of primary human hepatocytes on a commercially available, scalable platform
Limitations
- Proof-of-concept with a limited 17-compound panel
- External, inter-laboratory validation and cost-effectiveness analyses are pending
Future Directions: Broaden compound libraries (including diverse cosmetic classes), conduct multi-site validation and blinded challenges, benchmark against human clinical DILI incidence, and engage regulators for qualification.
Non-animal methods, including advanced in-vitro approaches such as liver-on-a-chip models, hold promise for hepatotoxicity testing but remain limited in pharmaceutical and regulatory adoption due to high costs, poor scalability, low reproducibility, and insufficient validation. To address these challenges, we introduce a drug-induced liver injury (DILI) model based on the commercially available and highly adaptable OC-Plex microfluidic platform. Primary human hepatocytes (PHHs) maintained long-term viability and metabolic
2. Prospective, Randomized, Double-Blind Assessment of Supramolecular Bakuchiol and Terminalia Chebula Extract for Facial Photoaging in Chinese Sensitive Skin Population.
In a 28-day randomized, double-blind study of 34 Chinese sensitive-skin participants, a serum combining supramolecular bakuchiol and Terminalia chebula significantly reduced TEWL, facial redness, and wrinkle metrics while increasing skin elasticity. No adverse events were observed, supporting tolerability in a population prone to irritation.
Impact: Provides RCT-level evidence for an anti-aging option tailored to sensitive Asian skin, addressing tolerability limitations of retinoids.
Clinical Implications: Clinicians and dermocosmetic practitioners can consider supramolecular bakuchiol with Terminalia chebula as a retinoid-sparing alternative for sensitive-skin photoaging.
Key Findings
- TEWL decreased by 24.90%; facial redness metrics decreased (a* −10.76%, redness percentage −31.81%).
- Wrinkle area −16.06%, SEw −16.71%, firmness F4 −25.60%, with elasticity R2 increased by 23.04% at Day 28.
- No adverse events reported; dermatologist assessments corroborated objective improvements.
Methodological Strengths
- Randomized, double-blind design with multiple objective biometrology endpoints
- Targeted enrollment of sensitive-skin population relevant to tolerability
Limitations
- Small sample size and single-ethnicity cohort
- Short duration (28 days) without long-term durability assessment
Future Directions: Head-to-head comparisons with retinoids, longer follow-up to assess durability and rebound, dose-ranging, and replication in multi-ethnic cohorts.
BACKGROUND AND AIMS: Asian skin is more sensitive than Caucasian. When it comes to anti-aging treatments, some classic actives like Retinoids, are not friendly to Asian skin due to irritation issues. Therefore, it becomes more important to research new active ingredients to address the aging concern of sensitive skin. To clinically assess the anti-aging, skin soothing, barrier function improvement efficacy of one novel formulation containing supramolecular Bakuchiol and Terminalia chebula extract in Chinese sensitive skin population. METHODS: A total of 34 sensitive skin subjects were enrolled in this clinical efficacy study. A routine consisting of twice daily topical applications of the test serum was followed for 28 days, evaluations were performed at baseline (D0) and after 8 h (T8h), 14 days (D14) and 28 days (D28) of using the regime. Objective skin assessment principles are skin sensitivity, barrier and aging. Sensitivity was evaluated by lactic acid sting test (LAST). Skin barrier evaluation, including transepidermal water loss (TEWL), a* value, and redness percentage. Aging evaluation, including wrinkle area, skin wrinkle (SEw), elasticity (R2), firmness (F4). As well as dermatologist evaluation of skin sensitivity and aging parameters and safety assessment. RESULTS: TEWL, a* value, redness percentage and mean score of LAST significantly reduced by 24.90%, 10.76%, 31.81%, 28.09%, respectively, and Dermatologist assessment significant decrease in facial redness, after 28 days of skin care treatment with the test serum. Wrinkle area, SEw, F4 significantly reduced by 16.06%, 16.71%, 25.60%, respectively, and Dermatologist assessment significant decrease in facial wrinkles, while R2 significantly increased by 23.04% after 28 days. No adverse events were reported. CONCLUSIONS: The serum containing supramolecular Bakuchiol and Terminalia chebula extract achieved skin rejuvenation in sensitive skin by improving sensitive and aging skin.
3. Treating Acne Scars in Fitzpatrick Skin Types I-VI Using a Novel 1550 nm Non-Ablative Resurfacing Laser With Focal Point Technology.
In a prospective multicenter study of 47 participants across Fitzpatrick I–VI, a new-generation 1550 nm non-ablative laser with conical-beam Focal Point Technology achieved significant blinded ECCA improvements and 78% GAIS-rated improvement without worsening cases. The device was well tolerated, with features designed to mitigate hyperpigmentation risk in darker skin.
Impact: Demonstrates effective, blinded improvements in acne scars across all skin phototypes, addressing safety gaps for darker skin where post-inflammatory hyperpigmentation risk is high.
Clinical Implications: Expands non-ablative resurfacing options for acne scars to Fitzpatrick V–VI with lower hyperpigmentation risk, supporting broader, safer adoption.
Key Findings
- Blinded ECCA score improved from 55.3 to 85.6 (p<0.0001); 90.2% achieved ≥15-point improvement.
- GAIS indicated 78.0% improved with no worsening cases.
- Two of three blinded reviewers correctly identified before/after photos in 92.7% of subjects; treatments were well tolerated.
Methodological Strengths
- Prospective multicenter design including Fitzpatrick I–VI
- Blinded outcome assessments (ECCA, photographic identification)
Limitations
- No randomized control or comparator arm
- Follow-up timing and long-term durability are not detailed in the abstract
Future Directions: Randomized comparisons versus fractional non-ablative standards, standardized follow-up for durability and PIH rates in darker phototypes, and cost-effectiveness analyses.
BACKGROUND: Acne scars have traditionally been treated with non-ablative fractional resurfacing lasers. Traditional 1550 nm lasers can be limited in energy delivery, skin cooling, and safety across all skin types. A new-generation 1550 nm non-ablative resurfacing laser was recently developed, employing conical beams for high energy delivery through Focal Point Technology. OBJECTIVE: To evaluate the utility of a 1550 nm non-ablative resurfacing laser using Focal Point Technology to improve acne scars in Fitzpatrick skin types I-VI. METHODS AND MATERIALS: A prospective, multi-center clinical study investigated this novel resurfacing laser using 1-6 treatments. RESULTS: Forty-seven subjects with Fitzpatrick skin types I-VI were enrolled and treated. Mean age was 40.2 years, and 59.6% were women. Based on GAIS, 78.0% were rated as improved, with none worsening. Two of three blinded reviewers correctly identified photographs for 92.7% of subjects. Significant improvement in blinded ECCA score was observed (85.6 vs. 55.3; p < 0.0001), with 90.2% achieving at least a 15-point improvement. Treatments were well tolerated. CONCLUSION: This new-generation 1550 nm non-ablative laser using Focal Point Technology with high energy delivery is safe and effective for acne scar treatment in all Fitzpatrick skin types. Its conical beams and cooling system significantly reduce hyperpigmentation risk in darker skin types.